Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 17, 2022 - Issue
Submit an article Journal homepage
103
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial

Andrea Gabrio1 UCL Statistical Science, University College London, London, UKView further author information
,
Necdet B Gunsoy2 Value Evidence & Outcomes, GlaxoSmithKline, Brentford, UKView further author information
,
Gianluca Baio1 UCL Statistical Science, University College London, London, UKORCID Iconhttps://orcid.org/0000-0003-4314-2570View further author information
ORCID Icon,
Alan Martin3 Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, UKORCID Iconhttps://orcid.org/0000-0002-3673-3383View further author information
ORCID Icon,
Victoria F Paly4 Global HTA, Health Economics, Reimbursement & Outcomes, ICON Plc., Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0003-3508-1296View further author information
ORCID Icon,
Nancy Risebrough5 Global HTA, Health Economics, Reimbursement & Outcomes, ICON plc., Toronto, ON, CanadaView further author information
,
David MG Halpin6 University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UKORCID Iconhttps://orcid.org/0000-0003-2009-4406View further author information
ORCID Icon,
Dave Singh7 The Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UKView further author information
,
Robert A Wise8 The Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-8353-2349View further author information
ORCID Icon,
MeiLan K Han9 University of Michigan, Pulmonary & Critical Care, Ann Arbor, MI, USAView further author information
,
Fernando J Martinez10 Joan and Sandy Weill Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2412-3182View further author information
ORCID Icon,
Gerard J Criner11 Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USAView further author information
,
Neil Martin12 Global Medical Affairs, GlaxoSmithKline, Uxbridge, UKView further author information
,
David A Lipson13 Development Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA;14 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0001-6732-4593View further author information
ORCID Icon &
Afisi S Ismaila15 Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA;16 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2876-8308View further author information
ORCID Icon show all
Pages 1633-1642 | Received 02 Oct 2021, Accepted 25 Jun 2022, Published online: 25 Jul 2022

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.1wms.pdf. Accessed November 26, 2019.
  • Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
  • Bogart MR, Hopson SD, Shih HC, Stanford RH, Coutinho AD. COPD exacerbation costs in the IMPACT study: a within-trial analysis. Am J Manag Care. 2020;26(5):e150–e154.
  • Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330. doi:10.1183/13993003.02165-2015
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
  • Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/COPD.S216072
  • Ismaila AS, Paly V, Schroeder M, et al. IMPACT study single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs – UK. Eur Respir J. 2018;52(Suppl 62):OA2128.
  • MIMS; 2018. Available from: https://www.mims.co.uk/. Accessed November 27, 2019.
  • Personal Social Services Research Unit. Unit costs of health and social care; 2017. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/. Accessed November 27, 2019.
  • National Health Service. National health service reference costs 2016/17; 2016. Available from: https://improvement.nhs.uk/resources/reference-costs/. Accessed November 27, 2019.
  • Rubin DB. Inference and missing data. Biometrika. 1976;63:581–592. doi:10.1093/biomet/63.3.581
  • Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
  • Gabrio A, Mason AJ, Baio G. A full Bayesian model to handle structural ones and missingness in economic evaluations from individual‐level data. Stat Med. 2019;8(38):1399–1420. doi:10.1002/sim.8045
  • Gabrio A, Mason AJ, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations. Pharmacoecon Open. 2017;1(2):79–97. doi:10.1007/s41669-017-0015-6
  • Leurent B, Gomes M, Carpenter JR. Missing data in trial‐based cost‐effectiveness analysis: an incomplete journey. Health Econ. 2018;27(6):1024–1040. doi:10.1002/hec.3654
  • Ismaila AS, Birk R, Shah D, et al. Once-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the FULFIL trial. Adv Ther. 2017;34(9):2163–2172. doi:10.1007/s12325-017-0604-x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.